Abay Kussainov

Abay Kussainov

Auto-generated profile, based on publicly available information

Abay Kussainov

Department of Neonatology, Asfendiyarov Kazakh National Medical University, Almaty 050012, Kazakhstan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2024 in Phytochemistry Reviews
Verified
Journal Article
Closed access
PDF file
UDUbaidilla Datkhayev
Ubaidilla Datkhayev
ZSZhanybek Shegebayev
Zhanybek Shegebayev
ATAknur Turgumbayeva
Aknur Turgumbayeva
ABAhmet Beyatli
Ahmet Beyatli
MDMyrzakozha Diyas
Myrzakozha Diyas
ZSZhanserik Shynykul
Zhanserik Shynykul

8 May 2026 in Global Health Action
Verified
Journal Article
Open access
SISaule Issenova
Saule Issenova
GAGulmira Altynbayeva
Gulmira Altynbayeva
AKAbay Kussainov
Abay Kussainov
GIGulzhan Issina
Gulzhan Issina
BBBalzira Bishekova
Balzira Bishekova
DSDilfuza Dilmuradovna Sultanmuratova
Dilfuza Dilmuradovna Sultanmuratova
Preterm birth, defined as delivery before 37 completed weeks of gestation, remains one of the most significant challenges in global maternal and neonatal health. Each year, an estimated 15 million ...

18 November 2025 in Medicina
Verified
Journal Article
Open access
PDF file
EKEdil Kurakbayev
Edil Kurakbayev
AKAbay Kussainov
Abay Kussainov
KUKuanysh Umbetov
Kuanysh Umbetov
YZYernur Zikiriya
Yernur Zikiriya
YSYergali Sarsekbayev
Yergali Sarsekbayev
ATArai Tolemisova
Arai Tolemisova
Background and Objectives: Childhood acute lymphoblastic leukemia (ALL) carries substantial morbidity, mortality, and economic burden, particularly in middle-income countries. The Pediatric Early Warning System (PEWS) is designed to trigger timely escalation of care, yet its independent impact on survival among critically ill leukemic children has not been well defined in Kazakhstan and Central Asia. Materials and Methods: We conducted a retrospective review all ICU admissions for patients aged 0–18 years with ALL at the National Center of Pediatrics, Almaty, across two periods: pre-implementation (January 2020–December 2022) and post-implementation of 24 h PEWS monitoring (September 2023–December 2024). The primary outcome was ICU mortality. Seven domains of covariates—demographic, clinical history, transfusion, vital signs, symptoms, laboratory, and instrumental data—were extracted. Univariable and multivariable logistic regression models were used to assess associations with mortality. Results: Among 255 admissions (105 during PEWS implementation; 150 prior to PEWS implementation), overall ICU mortality was 21.7%. After adjustment, PEWS implementation was not associated with reduced ICU mortality (AOR 0.89), despite a lower unadjusted mortality (15.9% vs. 26.6%). The most clinically relevant secondary findings included strong associations between mortality and bilateral pneumonia (AOR 7.45), ≥4 episodes of hyperthermia within 24 h of ICU admission (AOR 5.42), and systemic inflammatory response syndrome (AOR 4.61). Conclusions: These findings suggest that, within this high-acuity cohort, inflammatory and cardiorespiratory derangements outweigh any potential survival benefit from ward-based PEWS surveillance. Optimizing outcomes will require integrating early warning systems with timely deterioration management, focused cardiopulmonary support, and resource allocation tailored to the clinical context—rather than relying solely on surveillance scores.

30 December 2024 in Salud, Ciencia y Tecnología
Verified
Journal Article
Open access
PDF file
EKEdil Kurakbayev
Edil Kurakbayev
KUKuanysh Umbetov
Kuanysh Umbetov
YSYergali Sarsekbayev
Yergali Sarsekbayev
BTBotagoz Turdaliyeva
Botagoz Turdaliyeva
LMLyazat Manzhuova
Lyazat Manzhuova
GAGulnara Abdilova
Gulnara Abdilova
Aim: The aim is to highlight the importance of early detection, the efficacy of pediatric early warning signs (PEWS), and their implications for clinical practice, focusing on the specific signs that affect the detection and management of clinical deterioration in children with oncological diseases.Methods: The review included English-language studies retrieved from common databases using the keywords “pediatric,” “Early Warning Signs,” “clinical deterioration,” combined with terms related to “onchohematological” and “pediatric cancers.”Results: Sixteen articles were analyzed. The analysis revealed that the PEWS cohort was associated with a lower incidence of unplanned codes (p = 0.0001), cardiopulmonary arrest (P = 0.0001), and mortality (P = 0.01). The incidence of critical deterioration between the cohorts showed no significant variation (P = 0.07).Conclusion: PEWS significantly contributes to reducing mortality rates, unplanned codes, and cardiopulmonary arrest. However, further research is required to address the limitations and challenges associated with its application in this population

4 May 2026 in Cancer Epidemiology
Verified
Journal Article
Open access
SSSymbat Saliyeva
Symbat Saliyeva
LMLyazat Manzhuova
Lyazat Manzhuova
ABA.A. Bazarbayeva
A.A. Bazarbayeva
AKA.Z. Kussainov
A.Z. Kussainov
FSF.M. Sarsekbayeva
F.M. Sarsekbayeva
KTK.T. Taukebayev
K.T. Taukebayev
Studying the epidemiology of cancer in any country allows us to identify problems in the healthcare system as a whole and predict their future burden. However, no large-scale studies of the epidemiology of childhood cancer have been conducted in Kazakhstan to date. This study is the first to analyze cancer incidence rates among children in the Republic of Kazakhstan using data from the country's population-based registry of childhood cancers. We performed a population-based descriptive analysis of childhood cancer incidence in Kazakhstan from 2015 to 2024, using annual case counts and age-specific denominators from Electronic Registry of Oncological Patients (EROP). Incidence rates were calculated per 1,000,000 children; age-standardized rates used world-standard weights for ages 0-14 and 0-17. Temporal trends were measured by annual percent change (APC) via log-linear regression and average annual percent change (AAPC) with segmented log-linear regression. Between 2015 and 2024, EROP reported 507-638 childhood cancer cases annually, with crude incidence rates of 86.8-108.5 per 1,000,000 children (highest in 2017, lowest in 2019). The overall incidence remained stable (APC -1.20%/year, p = 0.112), and was consistently higher in males (IRR 1.13-1.48). Children aged 0-4 years had the highest age-specific incidence (123.5 per 1,000,000), while a significant decrease was seen in ages 10-14 (APC -1.99%/year, p = 0.014). Hepatic tumors increased (APC +3.86%/year, p = 0.044), retinoblastoma declined sharply (APC -8.61%/year, p = 0.001), with other groups showing no significant changes. Overall childhood cancer incidence in Kazakhstan remained broadly stable during 2015-2024, with consistently higher rates in males than females. Diagnosis-specific analyses identified increasing hepatic tumors and a marked decline in retinoblastoma, underscoring the importance of continued registry-based surveillance to monitor subtype-specific trends.

11 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SSSymbat Saliyeva
Symbat Saliyeva
LMLyazat Manzhuova
Lyazat Manzhuova
ABAigul Bazarbayeva
Aigul Bazarbayeva
AKAbay Kussainov
Abay Kussainov
FSFarida Sarsekbayeva
Farida Sarsekbayeva
DNDair Nurgaliev
Dair Nurgaliev
BackgroundStudying the epidemiology of cancer in any country allows us to identify problems in the healthcare system as a whole and predict their future burden. However, no large-scale studies of the epidemiology of childhood cancer have been conducted in Kazakhstan to date. This study is the first to analyze cancer incidence rates among children in the Republic of Kazakhstan using data from the country's population-based registry of childhood cancers.MethodsData on cancer cases diagnosed between the ages of 0 and 18 between 2015 and 2024 were obtained from the population-based cancer registry. Cases were grouped according to the International Classification of Childhood Cancer, 3rd edition (ICCC-3), based on morphology and primary anatomical site. Age-standardized incidence rates (ASR) were calculated using the direct standardization method and expressed per million children.ResultsThe overall average annual incidence rate among children in 2015-2024 was 102.6 cases per million, ranging from 85 to 107 cases. This rate was higher among boys (115.2 per million) than among girls (85.7 per million). When broken down by age, the incidence rates were highest among children aged 0-4 years. Leukemia, CNS tumors, and lymphomas were the most common diseases.ConclusionIn Kazakhstan, the incidence of cancer in children is lower than in developed countries. This study highlights the need for further research and understanding of differences in cancer patterns and risk factors in the region.